Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025)
Nasus Pharma (NSRX) reported Total Current Liabilities of $2.2 million for Q4 2025, down 44.95% on a YoY basis from $3.9 million in Q4 2024, and down 56.33% quarter-over-quarter from $5.0 million in Q2 2025.
Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Total Current Liabilities for 2 years, with the latest figure at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities fell 44.95% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (down 44.95% YoY), and the FY2025 full-year result was $2.2 million, down 44.95% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $2.2 million, down from $5.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $5.0 million in Q2 2025, with the low at $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | 2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.16 Mn |
| Jun 30, 2025 | 4.95 Mn |
| Dec 31, 2024 | 3.93 Mn |